Product image of Miochol-E (Acetylcholine Chloride) supplied by GNH India

Miochol-E

Active Ingredient:
Acetylcholine Chloride
Origin:
EU

Miochol-E (Acetylcholine Chloride)

Acetylcholine chloride, the active ingredient in Miochol‑E, is a cholinergic agonist presented as a sterile ophthalmic solution for intraocular use. Originating from the European Union market, it produces pupil constriction and facilitates aqueous humor outflow, thereby supporting intra‑operative miosis and adjunctive glaucoma therapy.

GNH India supplies Miochol‑E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured distribution across diverse healthcare settings and complying with local regulatory requirements through robust logistics and cold‑chain where applicable.

Manufacturer / TM Owner

Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Miochol‑E, a cholinergic agonist used in ophthalmic care, is indicated for conditions that benefit from pharmacologically induced pupil constriction and improved aqueous outflow.

  • Induction of miosis during ophthalmic surgery: provides controlled pupil constriction to enhance surgical visualization and instrument access.
  • Adjunctive treatment of glaucoma: facilitates aqueous humor drainage, helping to lower intraocular pressure when used with standard therapy.
  • Facilitation of intraocular procedures: aids in procedures such as laser iridotomy and intra‑ocular lens implantation by stabilizing pupil size.

How It Works

  • Acetylcholine chloride acts as a direct agonist at muscarinic (M3) receptors on the sphincter pupillae muscle. Stimulation of these receptors triggers intracellular calcium release, causing contraction of the circular muscle fibers and resulting in miosis. The same muscarinic activation in the ciliary body increases outflow of aqueous humor through the trabecular meshwork, contributing to intraocular pressure reduction.

Side Effects

Miochol‑E may cause ocular and systemic reactions; reported adverse events are categorized by frequency.

Common Side Effects

  • Eye irritation: mild burning or stinging sensation after instillation.
  • Transient blurred vision: temporary reduction in visual acuity.
  • Mild headache: occasional frontal discomfort.
  • Increased lacrimation: excess tearing.

Serious or Rare Side Effects

  • Severe ocular inflammation: uveitis or keratitis requiring immediate attention.
  • Systemic cholinergic toxicity: bradycardia, hypotension, or bronchospasm in susceptible individuals.

Precautions & Warnings

Prior to using Miochol‑E, clinicians should evaluate patient history and adhere to safety guidelines.

  • Contraindicated in patients with known hypersensitivity: avoid use.
  • Use with caution in narrow‑angle glaucoma: monitor intraocular pressure closely.
  • Avoid in severe cardiovascular disease: assess risk of systemic cholinergic effects.
  • Do not combine with other miotic agents without supervision: risk of excessive pupil constriction.
  • Store at room temperature: keep in the original container, protect from light and moisture.

Avoid Interactions

Miochol‑E can interact with other medications that affect cholinergic pathways or intraocular pressure.

Major Interactions (Avoid)

  • Concurrent use with systemic anticholinergic drugs: may reduce efficacy of Miochol‑E.
  • Combination with other cholinergic agonists: risk of excessive muscarinic stimulation.

Moderate Interactions (Monitor Closely)

  • Beta‑blocker eye drops: may have additive effects on intraocular pressure.
  • Topical anesthetics: may increase corneal irritation when used together.
  • Systemic cholinesterase inhibitors: monitor for enhanced cholinergic response.

Frequently Asked Questions

Miochol‑E is an intraocular solution containing acetylcholine chloride that is used to induce pupil constriction (miosis) during eye surgery, to support adjunctive treatment of glaucoma, and to facilitate various intraocular procedures by stabilising pupil size.

Acetylcholine chloride directly stimulates muscarinic receptors on the sphincter pupillae muscle, causing contraction and pupil constriction. It also activates muscarinic receptors in the ciliary body, enhancing aqueous humor outflow and helping to lower intraocular pressure.

The appropriate dose of Miochol‑E is determined by the prescribing ophthalmologist based on the specific surgical or therapeutic context, patient characteristics, and the desired degree of miosis. No fixed regimen is provided in public information.

The safety of Miochol‑E in pregnancy or while breastfeeding has not been established. It should be used only if the potential benefit justifies any potential risk to the mother or infant, and the decision should be made by a qualified healthcare professional.

To order Miochol‑E, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miochol‑E delivers acetylcholine chloride directly to the eye, providing rapid onset of miosis. Compared with indirect miotics such as pilocarpine, it acts as a direct muscarinic agonist, which can result in a more predictable pharmacodynamic response but may have a different side‑effect profile.

Store Miochol‑E at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from light and moisture, and avoid freezing. Follow any additional handling instructions provided on the label.

Miochol‑E is administered as a sterile intraocular solution. The ophthalmologist instills the prescribed amount directly into the eye or applies it to the ocular surface according to the procedure protocol, ensuring aseptic technique throughout.

Serious risks include severe ocular inflammation such as uveitis or keratitis, and systemic cholinergic toxicity manifesting as bradycardia, hypotension, or bronchospasm. Immediate medical attention is required if any of these events occur.

Miochol‑E should not be used in patients with a known hypersensitivity to acetylcholine chloride or any component of the formulation, and it should be avoided in individuals with severe cardiovascular disease or uncontrolled narrow‑angle glaucoma unless specifically directed by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.